Current Report Filing (8-k)
December 04 2017 - 3:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 28, 2017
Tetraphase Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware
|
|
001-35837
|
|
20-5276217
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
480 Arsenal Way
Watertown, Massachusetts
|
|
02472
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 715-3600
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if
the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
Item 5.02 (b). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On November 28, 2017 Patrick Horn, M.D., Ph.D. resigned his position as chief medical
officer of Tetraphase Pharmaceuticals, Inc. (the Company) in order to pursue other interests. Dr. Horns resignation is effective December 29, 2017. Larry Tsai, M.D., the Companys current vice president, clinical
development, will assume Dr. Horns duties.
Dr. Tsai joined the Company in 2014 as senior medical director and became vice president,
clinical development in 2015. He has provided significant leadership to the clinical team throughout the phase 3 IGNITE program for eravacycline as well as the early clinical development of the Companys pipeline programs. Dr. Tsai is also
a practicing physician at Brigham and Womens Hospital in Boston, Massachusetts and a part-time instructor in medicine at Harvard Medical School where he received his medical degree. He is board certified in critical care medicine, internal
medicine and pulmonary disease.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: December 4, 2017
|
|
|
|
By:
|
|
/s/ Maria D. Stahl
|
|
|
|
|
|
|
|
|
Maria D. Stahl
Senior Vice President, General Counsel
|
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Tetraphase Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Tetraphase Pharmaceuticals Inc News Articles